Multigene assay in diagnosis and treatment of node-negative breast cancer patients / 国际肿瘤学杂志

ABSTRACT

According to The National Comprehensive Cancer Network or St. Gallen criteria, many node-negative breast cancer patients are advised to receive chemotherapy, however, research has not demon-stinted that chemotherapy benefits all of them equally. Multigene assays, based on analysis about the genetic in-formation of tumors, are likely to provide doctors with a better understanding of the aggressiveness of individual tumors, and a better assessment of a patient's likely benefit from chemotherapy. Great progress has been made on the research of 21, 76, 70, 28 multigene assays. Among them, 21 gene assay is the most prospective,which has been recommended by The National Comprehensive Cancer Network in 2008 to use in the systemic adjuvant treatment decision in certain indications.